Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
This product will be launched through Granules Consumer Health (GCH) division
The product is expected to be launched in June 2023
Pheezee is designed to assess musculoskeletal and neuromuscular health.
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Study efficacy measures will include the expression of dystrophin protein and motor function.
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Rocuronium Bromide Injection is a neuromuscular blocking agent
Subscribe To Our Newsletter & Stay Updated
